Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.

Bromodomain-containing proteins of the BET family recognize histone lysine acetylation and mediate transcriptional activation of target genes such as the MYC oncogene. Pharmacological inhibitors of BET domains promise therapeutic benefits in a variety of cancers. We performed a high-diversity chemical compound screen for agents capable of modulating BRD4-dependent heterochromatization of a generic reporter in human cells. In addition to known and new compounds targeting BRD4, we identified small molecules that mimic BRD4 inhibition without direct engagement. One such compound was a potent inhibitor of the second bromodomain of TAF1. Using this inhibitor, we discovered that TAF1 synergizes with BRD4 to control proliferation of cancer cells, making TAF1 an attractive epigenetic target in cancers driven by MYC.

[1]  D. Reinberg,et al.  Functional Characterization of Core Promoter Elements: the Downstream Core Element Is Recognized by TAF1 , 2005, Molecular and Cellular Biology.

[2]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[3]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[4]  M. Donohoe,et al.  The BET Family Member BRD4 Interacts with OCT4 and Regulates Pluripotency Gene Expression , 2015, Stem cell reports.

[5]  Ian Collins,et al.  Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.

[6]  S. Peña-Llopis,et al.  A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth , 2013, Nature Communications.

[7]  S. Knapp,et al.  Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.

[8]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Superti-Furga,et al.  Gene essentiality and synthetic lethality in haploid human cells , 2015, Science.

[10]  Wei Zhang,et al.  Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors , 2014, Journal of medicinal chemistry.

[11]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[12]  S. Knapp,et al.  [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains , 2013, Journal of medicinal chemistry.

[13]  M. Gustafsson,et al.  Subdiffraction Multicolor Imaging of the Nuclear Periphery with 3D Structured Illumination Microscopy , 2008, Science.

[14]  S. Knapp,et al.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses , 2015, Proceedings of the National Academy of Sciences.

[15]  E. Lander,et al.  Identification and characterization of essential genes in the human genome , 2015, Science.

[16]  K. Gupta,et al.  More pieces to the puzzle: recent structural insights into class II transcription initiation. , 2014, Current opinion in structural biology.

[17]  Jonathan T Seal,et al.  Identification of a Novel Series of BET Family Bromodomain Inhibitors: Binding Mode and Profile of I‐BET151 (GSK1210151A). , 2012 .

[18]  Philip R. Gafken,et al.  Phosphorylation-Dependent Regulation of Cyclin D1 and Cyclin A Gene Transcription by TFIID Subunits TAF1 and TAF7 , 2012, Molecular and Cellular Biology.

[19]  M. Bielefeld-Sévigny.  AlphaLISA immunoassay platform- the "no-wash" high-throughput alternative to ELISA. , 2009, Assay and drug development technologies.

[20]  L. Wodicka,et al.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.

[21]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[22]  Marjan S. Bolouri,et al.  Integrated Analysis of Protein Composition, Tissue Diversity, and Gene Regulation in Mouse Mitochondria , 2003, Cell.

[23]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[24]  Anne E Carpenter,et al.  The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling , 2013, Nature.

[25]  G. Ganji,et al.  BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.

[26]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[27]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[28]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Jianxin You,et al.  Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-order Chromatin Structure* , 2012, The Journal of Biological Chemistry.

[30]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[31]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[32]  J. Beutler,et al.  Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay , 2010, Journal of biomedicine & biotechnology.

[33]  Darryl J Pappin,et al.  BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. , 2015, Molecular cell.

[34]  Qiang Zhou,et al.  Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.

[35]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[36]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[37]  Gaurav D. Gaiha,et al.  Reactivation of latent HIV-1 by inhibition of BRD4. , 2012, Cell reports.

[38]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[39]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[40]  Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain , 2014 .

[41]  P. Sebastiani,et al.  BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1 , 2012, Journal of leukocyte biology.

[42]  P. Bamborough,et al.  Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. , 2013, Journal of medicinal chemistry.

[43]  R. Kurzrock,et al.  KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. , 1995, Leukemia.

[44]  S. Knapp,et al.  Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription , 2014, Cell reports.

[45]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[46]  S. Knapp,et al.  Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family , 2012, Bioorganic & medicinal chemistry.

[47]  Shwu‐Yuan Wu,et al.  The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation* , 2007, Journal of Biological Chemistry.

[48]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[49]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[50]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[51]  Christopher P Austin,et al.  A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. , 2008, Analytical biochemistry.

[52]  Dimos Gaidatzis,et al.  Step-Wise Methylation of Histone H3K9 Positions Heterochromatin at the Nuclear Periphery , 2012, Cell.

[53]  P. Young,et al.  RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist , 2013, PloS one.

[54]  B. Göttgens,et al.  Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells , 2015, Science.

[55]  Andrew J. Bannister,et al.  Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. , 2015, Cancer research.